Can reprogrammed immune cells silence lupus? a small trial aims to find out.
NCT ID NCT07720310
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This trial tests whether anti-CD19 CAR-T cell therapy can put severe lupus into remission. The treatment involves taking a patient's own immune cells, engineering them to target and destroy faulty B cells, and infusing them back. The study enrolls 12 adults with refractory systemic lupus erythematosus who have not responded to at least two prior therapies. Researchers will measure disease activity and serologic remission to see if this one-time cell therapy can replace lifelong medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- anti-CD19 CAR-T cells (academic CAR-T product made with a lentiviral vector)
- What this could lead to
- If successful, this could offer a durable, drug-free remission for people with severe lupus that hasn't responded to standard treatments.
- What could go wrong
- This is a very early, small trial with only 12 participants. CAR-T therapy carries risks like cytokine release syndrome and neurotoxicity, and it may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEM LUPUS ERYTHEMATOSUS(SLE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NN Alexandrov National Cancer Centre of Belarus
Lyasny, Minsk Oblast, 223040, Belarus
More trials for these conditions
Other studies related to the condition(s) this trial covers.